Form D · Pharmaceuticals

Virdante Pharmaceuticals, Inc.

Cambridge, MA · CIK 0001427733

Offering snapshot reported Oct 14, 2011 · SEC filing

Reported sold: $30.1M
Investors reported: 10
Minimum accepted: $0
First sale: Jan 30, 2008

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 14, 2011	Amendment	$30,075,000	$0vs Oct 21, 2010	10	SEC filing
Oct 21, 2010	Amendment	$30,075,000	$0vs Oct 29, 2009	10	SEC filing
Oct 29, 2009	Amendment	$30,075,000	No comparison	10	SEC filing
Feb 15, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
Feb 15, 2008	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity
Exemptions: 06
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-114968

Source: Form D, filed Oct 14, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Eric Aguiar	Director
L. Patrick Gage	Director
Anders Hove	Director
John Ripple	Director, Executive
Michael Steinmetz	Director
Gail Wasserman	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

101 Main Street Suite 1210
Cambridge, MA, 02142